Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Quentin Delcros, Matthieu Groh, Mouhamad Nasser, Jean-Emmanuel Kahn & Vincent Cottin. (2021) Steroid alternatives for managing eosinophilic lung diseases. Expert Opinion on Orphan Drugs 9:7-10, pages 205-218.
Read now
Read now
G Daniel Brooks. (2020) Updated Evaluation of Dupilumab in the Treatment of Asthma: Patient Selection and Reported Outcomes. Therapeutics and Clinical Risk Management 16, pages 181-187.
Read now
Read now
Angela Moran & Ian D Pavord. (2020) Anti-IL-4/IL-13 for the treatment of asthma: the story so far. Expert Opinion on Biological Therapy 20:3, pages 283-294.
Read now
Read now
Patrick Mitchell & Richard Leigh. (2019) A drug safety review of treating eosinophilic asthma with monoclonal antibodies. Expert Opinion on Drug Safety 18:12, pages 1161-1170.
Read now
Read now
Articles from other publishers (34)
Jamie Katy Hu, Marita Yaghi, Clara Milikowski & Scott Andrew Elman. (2023) Eosinophilic granulomatosis and polyangiitis unmasked by dupilumab. International Journal of Dermatology 62:6, pages 839-840.
Crossref
Crossref
Jun-Hong Tsai & Tsen-Fang Tsai. (2023) A Review of Dupilumab-Induced Adverse Events to Dermatologists and the Potential Pathogenesis in the Treatment of Atopic Dermatitis. Dermatitis®.
Crossref
Crossref
D. A. Sivokhin, E. S. Shchennikova, V. V. Royuk & N. P. Kniajeskaia. (2023) Dupilumab in complex therapy for chronic rhinosinusitis with nasal polyps and asthma. Meditsinskiy sovet = Medical Council:7, pages 203-208.
Crossref
Crossref
Jakub Novosad, Irena Krčmová, Ondřej Souček, Marcela Drahošová, Vratislav Sedlák, Martina Kulířová & Pavlína Králíčková. (2023) Subsets of Eosinophils in Asthma, a Challenge for Precise Treatment. International Journal of Molecular Sciences 24:6, pages 5716.
Crossref
Crossref
Sonia Mathew, Timothy Kubal & Farnaz Tabatabaian. (2023) Worsening hypereosinophilia with use of dupilumab. Annals of Allergy, Asthma & Immunology 130:3, pages 272-275.
Crossref
Crossref
Shinji Mitsuyama & Tetsuya Higuchi. (2023) Effectiveness of dupilumab for chronic prurigo in elderly patients with atopic dermatitis. Anais Brasileiros de Dermatologia 98:1, pages 86-89.
Crossref
Crossref
Lorenzo Salvati, Francesco Liotta, Francesco Annunziato & Lorenzo Cosmi. (2022) Therapeutical Targets in Allergic Inflammation. Biomedicines 10:11, pages 2874.
Crossref
Crossref
Megan E. Milne, Jack Kimball, Teresa K. Tarrant, Rami N. Al-Rohil & David L. Leverenz. (2022) The Role of T Helper Type 2 (Th2) Cytokines in the Pathogenesis of Eosinophilic Granulomatosis with Polyangiitis (eGPA): an Illustrative Case and Discussion. Current Allergy and Asthma Reports 22:11, pages 141-150.
Crossref
Crossref
Charlie Bridgewood, Miriam Wittmann, Tom Macleod, Abdulla Watad, Darren Newton, Kanchan Bhan, Howard Amital, Giovanni Damiani, Sami Giryes, Nicola Luigi Bragazzi & Dennis McGonagle. (2022) T Helper 2 IL-4/IL-13 Dual Blockade with Dupilumab Is Linked to Some Emergent T Helper 17‒Type Diseases, Including Seronegative Arthritis and Enthesitis/Enthesopathy, but Not to Humoral Autoimmune Diseases. Journal of Investigative Dermatology 142:10, pages 2660-2667.
Crossref
Crossref
William W. Busse. (2022) Dupilumab and Eosinophils: A Red Flag?. The Journal of Allergy and Clinical Immunology: In Practice 10:10, pages 2710-2712.
Crossref
Crossref
Yuki Nishiyama, Toshiyuki Koya, Kei Nagano, Seitaro Abe, Yosuke Kimura, Kenjiro Shima, Mio Toyama-Kosaka, Takashi Hasegawa, Takanobu Sasaki, Kaori Shinbori, Shigeharu Ueki, Kaori Takamura & Toshiaki Kikuchi. (2022) Two cases of dupilumab-associated eosinophilic pneumonia in asthma with eosinophilic chronic rhinosinusitis: IL-5-driven pathology?. Allergology International 71:4, pages 548-551.
Crossref
Crossref
Harish Dharmarajan, Oluleke Falade, Stella E. Lee & Eric W. Wang. (2022) Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. International Forum of Allergy & Rhinology 12:8, pages 986-995.
Crossref
Crossref
Anna Kychygina, Myriam Cassagne, Marie Tauber, Stéphane Galiacy, Carle Paul, Pierre Fournié & Michel Simon. (2022) Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases. Clinical Reviews in Allergy & Immunology 62:3, pages 519-533.
Crossref
Crossref
Diego Bagnasco, Elisa Testino, Stefania Nicola, Laura Melissari, Maria Russo, Rikki Frank Canevari, Luisa Brussino & Giovanni Passalacqua. (2022) Specific Therapy for T2 Asthma. Journal of Personalized Medicine 12:4, pages 593.
Crossref
Crossref
Miki Ikeda, Nobuharu Ohshima, Masahiro Kawashima, Meiko Shiina, Masashi Kitani & Maho Suzukawa. (2022) Severe Asthma Where Eosinophilic Granulomatosis with Polyangiitis Became Apparent after the Discontinuation of Dupilumab. Internal Medicine 61:5, pages 755-759.
Crossref
Crossref
Michael Frohlich, Ron Olivenstein & Maxime Cormier. (2022) Eosinophilic pulmonary complications of dupilumab in 2 patients with asthma and chronic rhinosinusitis with nasal polyps. The Journal of Allergy and Clinical Immunology: In Practice 10:2, pages 617-619.
Crossref
Crossref
Abhishek Gadre & Praveen Akuthota. 2022. Eosinophilic Lung Diseases. Eosinophilic Lung Diseases
141
152
.
Carlo Lombardi, Alvise Berti & Marcello Cottini. (2022) The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions. Current Research in Immunology 3, pages 42-53.
Crossref
Crossref
Hideyasu Shimizu, Masamichi Hayashi, Hisayuki Kato, Mitsuru Nakagawa, Kazuyoshi Imaizumi & Mitsushi Okazawa. (2021) IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma. International Journal of Molecular Sciences 22:20, pages 11209.
Crossref
Crossref
Marek Lommatzsch, Paul Stoll, Jörg Winkler, Daniel Zeise‐Wehry, Michael Tronnier, Marc‐André Weber & J. Christian Virchow. (2021) Eosinophilic pleural effusion and stroke with cutaneous vasculitis: Two cases of dupilumab‐induced hypereosinophilia. Allergy 76:9, pages 2920-2923.
Crossref
Crossref
Yael Ben‐David, Lea Bentur, Michal Gur, Anat Ilivitzki, Guy Gut, Yazeed Toukan, Vered Nir, George Shallufi & Ronen Bar‐Yoseph. (2021) Reverse butterfly pattern image with eosinophilia: Effective treatment with benralizumab—A case report. Pediatric Pulmonology 56:8, pages 2736-2739.
Crossref
Crossref
Katrien Eger, Lodewijk Pet, Els J.M. Weersink & Elisabeth H. Bel. (2021) Complications of switching from anti–IL-5 or anti–IL-5R to dupilumab in corticosteroid-dependent severe asthma. The Journal of Allergy and Clinical Immunology: In Practice 9:7, pages 2913-2915.
Crossref
Crossref
Eriko Ogino & Hirotaka Yasuba. (2021) Severe Relapsing Eosinophilic Chronic Rhinosinusitis with Asthma Treated Consecutively with Inhaled Corticosteroids Exhaled through the Nose, Followed by Mepolizumab and Dupilumab気管支喘息を合併した難病指定好酸球性副鼻腔炎再発例に対する生物学的製剤と経鼻呼出法による治療. Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology) 60:4, pages 538-545.
Crossref
Crossref
Safwat A.M. Eldaabossi, Amgad Awad & Neda'a Anshasi. (2021) Mepolizumab and dupilumab as a replacement to systemic glucocorticoids for the treatment of Chronic Eosinophilic Pneumonia and Allergic Bronchopulmonary Aspergillosis - Case series, Almoosa specialist hospital. Respiratory Medicine Case Reports 34, pages 101520.
Crossref
Crossref
Christopher Fowler & Wynton Hoover. (2020) Dupilumab for chronic eosinophilic pneumonia. Pediatric Pulmonology 55:12, pages 3229-3230.
Crossref
Crossref
Ludger Klimek, Magdalena Spielhaupter, Ali Alali, Marc Cichy, Tilman Huppertz & Jan Hagemann. (2020) Eosinophilie unter Dupilumab bei chronischer Rhinosinusitis mit Polyposis nasi und Asthma bronchiale. Laryngo-Rhino-Otologie 99:11, pages 811-812.
Crossref
Crossref
Bianca Olivieri, Elisa Tinazzi, Marco Caminati & Claudio Lunardi. (2020) Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders. Immunology and Allergy Clinics of North America 40:4, pages 649-665.
Crossref
Crossref
N. M. Nenasheva, O. M. Kurbacheva, S. N. Avdeev, S. V. Fedosenko, A. V. Emel’yanov, A. S. Belevskiy, N. I. Il'ina, N. P. Knyazheskaya, S. K. Zyryanov, G. L. Ignatova, I. V. Demko, L. V. Shul'zhenko, I. V. Leshchenko, R. S. FassakhovB. A. Chernyak, N. G. Nedashkovskaya, E. N. Bobrikova & D. V. Demina. (2020) Practical recommendations for choosing an immunobiological preparation for the treatment of severe bronchial asthma of T2-endotype. Russian Pulmonology 30:2, pages 227-244.
Crossref
Crossref
Masaya Iwamuro, Toshi Murakami, Takehiro Tanaka, Shohei Oka, Seiji Kawano, Yoshiro Kawahara & Hiroyuki Okada. (2020) Eosinophilic Gastritis in a Patient Previously Treated with Dupilumab. Case Reports in Gastrointestinal Medicine 2020, pages 1-4.
Crossref
Crossref
Kohsuke Isomoto, Tomohisa Baba, Akimasa Sekine, Naoto Aiko & Takashi Ogura. (2020) Promising Effects of Benralizumab on Chronic Eosinophilic Pneumonia. Internal Medicine 59:9, pages 1195-1198.
Crossref
Crossref
Diego Bagnasco, Marco Caminati & Giovanni Passalacqua. (2020) Biologicals for severe asthma: what we can learn from real-life experiences?. Current Opinion in Allergy & Clinical Immunology 20:1, pages 64-70.
Crossref
Crossref
Hani Harb & Talal A. Chatila. (2019) Mechanisms of Dupilumab. Clinical & Experimental Allergy 50:1, pages 5-14.
Crossref
Crossref
Dinesh Yogaratnam, Katherine M. Carey, Valerie Coppenrath, Aimee Dawson, Daniel Havkins, Amy B.W. LaMothe & Ann M. Lynch. 2020. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
171
181
.
. (2019) Dupilumab. Reactions Weekly 1772:1, pages 146-146.
Crossref
Crossref